Leerink Partners analyst Jonathan Chang maintained a Buy rating on Zai Lab (NASDAQ:ZLAB) on Tuesday, setting a price target of $202, which is approximately 13.70% above the present share price of $177.66.
Chang expects Zai Lab to post earnings per share (EPS) of -$2.64 for the second quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Zai Lab, with an average price target of $221.05.
The analysts price targets range from a high of $250 to a low of $202.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $20.1 million and a net profit of -$227.09 million. The company's market cap is $13.39 billion.
According to TipRanks.com, Leerink Partners analyst Jonathan Chang is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 23.2% and a 51.28% success rate.
Zai Lab Ltd. is a biopharmaceutical company, which engages in the licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need. Its product pipelines include ZL-2306, ZL-2401, FPA144, ETX2514, and ZL-2301. The company was founded by Samantha Ying Du and Marietta Wu in 2014 and is headquartered in Shanghai, China.